Exozymes EXOZ Insider Ownership

Updated Oct 27, 2026

Over the past 12 months, Exozymes insiders bought $6,405 of stock on the open market (855 shares) and sold $34,851 (5.23K shares).

• Exozymes' open-market purchases in the past 12 months came from one insider, and its sales from 2 insiders.
• Among Exozymes' insiders, Michael Heltzen (Chief Executive Officer) was the largest open-market buyer over the past 12 months, purchasing $6,405 of stock (855 shares), most recently on August 26, 2026.
• On the selling side, Damien Alan Perriman (Chief Commercial Officer) was the top open-market seller of Exozymes over the past 12 months, with $19,427 sold (3.73K shares) and the latest sale on October 12, 2026.
• Outside the open market, Exozymes insiders received 33.06K shares in stock awards and acquired 56.5K shares through option exercises and conversions over the past 12 months.
• Business Quant data shows Exozymes insiders holding 5.36Mn shares in total in their latest Form 4 filings, or 57.72% of the 9.28Mn shares outstanding; that total is up 0.60% from 5.33Mn shares at the end of Q2 2026 and up 0.86% from 5.31Mn shares at the end of Q3 2025.
• None of the 5.36Mn shares held by Exozymes insiders is held through trusts, partnerships or family members; all are direct holdings.
• Business Quant counts 6 insiders with holdings in Exozymes stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• EXOZ's three largest insider shareholders, per their latest Form 4 filings, are MDB Capital Holdings, LLC (10% owner, 3.93Mn shares), Tyler Paz Korman (Chief Scientific Officer, 729.12K shares) and Paul Hideo Opgenorth (Vice President, Development, 645.15K shares).
• Of the shares held by EXOZ insiders, 73.38% belong to MDB Capital Holdings, LLC.
• Over the past 12 months, 11 insiders reported transactions in Exozymes stock in 17 Form 4 filings.
• Insider figures for EXOZ include Form 4 filings through October 26, 2026.